Literature DB >> 30332514

The prognostic significance of adrenocortical carcinomas identified incidentally.

Kara K Rossfeld1, Shishir K Maithel2, Jason Prescott3, Tracy S Wang4, Ryan C Fields5, Sharon M Weber6, Jason K Sicklick7, Adam C Yopp8, Quan-Yang Duh9, Carmen C Solorzano10, Konstantinos I Votanopoulos11, Ioannis Hatzaras12, George A Poultsides13, Lawrence A Shirley1.   

Abstract

BACKGROUND AND OBJECTIVES: Little is known regarding the difference in prognosis among patients who have an incidentally discovered adrenocortical carcinoma (ACC) vs those who present with signs or symptoms. We aimed to explore differences in the outcomes of these two populations.
METHODS: Data were collected on patients who underwent resection of ACC at 1 of 13 institutions between January 1993 and December 2014. Presentations were categorized as incidental vs symptomatic and outcomes were compared.
RESULTS: Among 227 patients, 100 were diagnosed incidentally while 127 patients presented with symptoms/signs. Clinical and pathological features were comparable among incidental vs nonincidental patients with ACC following the exceptions. Patients with incidentalomas were more likely to have a T1/T2 tumor (55.8% vs 34.8%; P < 0.01) and less likely to have a functional tumor (33.7% vs 47.9%; P = 0.04). Patients with an incidental ACC had improved median recurrence-free survival (RFS; 29.4 months) compared with patients with a nonincidental ACC (13.0 months; P = 0.03); however, on multivariable analysis, incidental ACC was not an independent predictor of survival.
CONCLUSIONS: Patients with resected ACC identified incidentally had an improved RFS compared with the patients who presented with symptoms or signs. This difference may be related to the patients with incidental tumors having earlier T-stage disease.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  carcinoma; functional; hormone; incidentaloma; symptomatic

Mesh:

Year:  2018        PMID: 30332514     DOI: 10.1002/jso.25274

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  5 in total

1.  The clinical utility of 'GRAS' parameters in stage I-III adrenocortical carcinomas: long-term data from a high-volume institution.

Authors:  Jiayu Liang; Zhihong Liu; Liang Zhou; Yongquan Tang; Chuan Zhou; Kan Wu; Fuxun Zhang; Fan Zhang; Xin Wei; Yiping Lu; Yuchun Zhu
Journal:  Endocrine       Date:  2019-11-30       Impact factor: 3.633

2.  Clinicopathological features and outcomes of adrenocortical carcinoma: A single institution experience.

Authors:  Lekha Madhavan Nair; K M Jagathnath Krishna; Aswin Kumar; Susan Mathews; John Joseph; Francis Vadakkumparambil James
Journal:  Indian J Urol       Date:  2019 Jul-Sep

3.  A nomogram for individualized estimation of survival among adult patients with adrenocortical carcinoma after surgery: a retrospective analysis and multicenter validation study.

Authors:  Jianqiu Kong; Junjiong Zheng; Jinhua Cai; Shaoxu Wu; Xiayao Diao; Weibin Xie; Xiong Chen; Chenyi Liao; Hao Yu; Xinxiang Fan; Chaowen Huang; Zhuowei Liu; Wei Chen; Qiang Lv; Haide Qin; Jian Huang; Tianxin Lin
Journal:  Cancer Commun (Lond)       Date:  2019-11-27

Review 4.  Open versus minimally invasive surgery for suspected adrenocortical carcinoma.

Authors:  Dylan M Buller; Alex M Hennessey; Benjamin T Ristau
Journal:  Transl Androl Urol       Date:  2021-05

5.  Histological scores and tumor size on stage II in adrenocortical carcinomas.

Authors:  Rui Caetano Oliveira; Maria João Martins; Carolina Moreno; Rui Almeida; João Carvalho; Paulo Teixeira; Miguel Teixeira; Edgar Tavares Silva; Isabel Paiva; Arnaldo Figueiredo; Maria Augusta Cipriano
Journal:  Rare Tumors       Date:  2021-06-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.